Why have a CR when we have enough cash?, page-28

"The last two bioshares reports has mentioned a possible her vaxx combination trial with herceptin."

That could work I guess. It was once listed in an imu presentation I think. I seem to recall it was a sponsored trial too (ie paid for by somebody else (Roche?)). I can look for it if you want me to.

I've always thought that Genentech (Roche) or GSK (because of AH) the most likely suitors.

Perhaps now, with cf33 too, somebody will make a move.

Imugene have so many drugs, a huge pipeline and so much ip - taking over imu is like taking over five other biotechs!